DrugBank

MAY 22, 2024

In the dynamic world of drug discovery, the notion of "undruggable" targets presents both a significant challenge and an intriguing frontier for researchers and pharmaceutical companies. Beyond Proteins: DNA and RNA Frontier The story doesn’t end with proteins.

Small Molecule 96

Small Molecule RNA DNA Pharmaceutical Companies 96

DrugBank

OCTOBER 17, 2024

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

Drug Target Review

JUNE 19, 2024

Also, many companies never reached the point where they received validation from big pharmaceutical companies. Transplanting cells could prove to be more beneficial than treating a particular condition with a small molecule or an antibody, and that really speaks to the power of cell therapy.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Target Review

JULY 18, 2023

I think it is astonishing that The Human Genome Project was completed exactly 20 years ago and DNA was discovered by Franklin and published by Watson and Crick exactly 70 years ago, yet that 10 percent success rate has still not improved. With support from pharmaceutical companies, ultimately, the answer to this question should be yes.

Drug Development 98

Drug Development Drugs Clinical Development Pharmaceutical Companies 98

Elrig

APRIL 29, 2024

Harini Srinivasan is a Principal Scientific Associate at Serna Bio with over 10 years of research experience in academic institutions, health care organizations and pharmaceutical companies. There, I supported AI-enabled DD efforts in their small molecule portfolio.

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

Drug Target Review

APRIL 16, 2024

By delivering radiation directly to the tumour cells, RLT can induce DNA damage, leading to cell death and tumour regression. Peptides are relatively small molecules compared to mAbs, making them easier and less costly to produce and modulate. In contrast, development of mAbs is typically resource intensive.

Small Molecule 59

Small Molecule Therapies Treatment Pharmaceutical Companies 59

DrugBank

FEBRUARY 26, 2025

In response, researchers and pharmaceutical companies are exploring novel approaches to antibiotic development. Over the past two decades, many pharmaceutical companies have deprioritized antibiotic research due to high development costs and lower profitability compared to treatments for chronic diseases.

Therapies 52

Therapies Pharmaceutical Companies Pharmacokinetics Treatment 52